Selinexor

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 620 publications

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2A r and NPM1 -m AML.

Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2A r and NPM1 -m AML.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Development and Preclinical Evaluation of a Selinexor-Derived Radiotracer [68Ga]Ga-NOTA-Selinexor for Imaging XPO1 Expression in Multiple Myeloma.

Development and Preclinical Evaluation of a Selinexor-Derived Radiotracer [68Ga]Ga-NOTA-Selinexor for Imaging XPO1 Expression in Multiple Myeloma.

Journal: Molecular pharmaceutics

Published: April 02, 2026

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Journal: Neuro-oncology pediatrics

Published: March 27, 2026

Simultaneous determination of selinexor， posaconazole， venetoclax， and voriconazole in human plasma using ultra-high performance liquid chromatography-tandem mass spectrometry

Simultaneous determination of selinexor， posaconazole， venetoclax， and voriconazole in human plasma using ultra-high performance liquid chromatography-tandem mass spectrometry

Journal: Se pu = Chinese journal of chromatography

Published: March 12, 2026

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.

Journal: Annals of medicine

Published: February 28, 2026

Early use of selinexor-bortezomib-dexamethasone after anti-CD38-based therapy in multiple myeloma: a case report.

Early use of selinexor-bortezomib-dexamethasone after anti-CD38-based therapy in multiple myeloma: a case report.

Journal: Recenti progressi in medicina

Published: February 20, 2026

Deep and durable response with the selinexor-bortezomib-dexamethasone combination in a patient with multiple myeloma refractory to first-line treatment.

Deep and durable response with the selinexor-bortezomib-dexamethasone combination in a patient with multiple myeloma refractory to first-line treatment.

Journal: Recenti progressi in medicina

Published: February 20, 2026

XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells.

XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 03, 2026

In reply: Why selinexor remains a subpar option.

In reply: Why selinexor remains a subpar option.

Journal: The oncologist

Published: January 28, 2026

Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting.

Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting.

Journal: Journal of hematology & oncology

Published: January 12, 2026

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: January 05, 2026

PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma.

PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma.

Journal: Bioorganic chemistry

Published: December 17, 2025

Showing 1-12 of 620

Last Updated: 04/28/2026